Mizuho cut shares of Amedisys Inc (NASDAQ:AMED) from a buy rating to a neutral rating in a research note issued to investors on Wednesday morning, MarketBeat reports. Mizuho currently has $50.00 price objective on the health services provider’s stock.

AMED has been the topic of several other reports. Royal Bank Of Canada reissued a hold rating and issued a $56.00 target price on shares of Amedisys in a research report on Monday, June 5th. BidaskClub downgraded Amedisys from a strong-buy rating to a buy rating in a research report on Wednesday, July 12th. Stephens upped their target price on Amedisys from $50.00 to $54.00 and gave the company an equal weight rating in a research report on Thursday, May 4th. Benchmark Co. reissued a hold rating and issued a $57.00 target price (up from $50.00) on shares of Amedisys in a research report on Wednesday, May 3rd. Finally, Zacks Investment Research downgraded Amedisys from a buy rating to a hold rating in a research report on Tuesday, May 2nd. Five investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. The stock presently has a consensus rating of Buy and a consensus target price of $56.50.

Amedisys (NASDAQ:AMED) opened at 46.66 on Wednesday. The stock has a 50 day moving average price of $60.41 and a 200-day moving average price of $54.02. The stock has a market capitalization of $1.58 billion, a P/E ratio of 39.88 and a beta of 0.94. Amedisys has a 1-year low of $34.58 and a 1-year high of $65.91.

Amedisys (NASDAQ:AMED) last issued its quarterly earnings data on Wednesday, July 26th. The health services provider reported $0.62 EPS for the quarter, beating the consensus estimate of $0.50 by $0.12. Amedisys had a return on equity of 13.71% and a net margin of 2.70%. The firm had revenue of $378.80 million during the quarter, compared to analyst estimates of $380.80 million. During the same quarter in the prior year, the business posted $0.42 EPS. The business’s revenue for the quarter was up 5.0% compared to the same quarter last year. Equities research analysts expect that Amedisys will post $2.14 EPS for the current year.

COPYRIGHT VIOLATION NOTICE: This report was published by Watch List News and is the sole property of of Watch List News. If you are accessing this report on another site, it was copied illegally and reposted in violation of United States & international copyright law. The correct version of this report can be viewed at https://www.watchlistnews.com/mizuho-downgrades-amedisys-inc-nasdaqamed-to-neutral/1462687.html.

In related news, Director Bruce D. Perkins purchased 500 shares of the business’s stock in a transaction on Thursday, May 25th. The shares were bought at an average cost of $59.69 per share, with a total value of $29,845.00. Following the transaction, the director now owns 13,331 shares of the company’s stock, valued at $795,727.39. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Jake L. Netterville sold 10,000 shares of the stock in a transaction dated Friday, May 12th. The stock was sold at an average price of $60.00, for a total value of $600,000.00. Following the sale, the director now directly owns 77,499 shares in the company, valued at $4,649,940. The disclosure for this sale can be found here. Insiders have sold a total of 56,828 shares of company stock worth $3,350,922 over the last ninety days. 2.80% of the stock is owned by insiders.

A number of large investors have recently made changes to their positions in AMED. Sivik Global Healthcare LLC increased its stake in shares of Amedisys by 60.9% in the first quarter. Sivik Global Healthcare LLC now owns 34,607 shares of the health services provider’s stock valued at $1,768,000 after buying an additional 13,097 shares in the last quarter. OppenheimerFunds Inc. increased its stake in shares of Amedisys by 3.5% in the first quarter. OppenheimerFunds Inc. now owns 446,147 shares of the health services provider’s stock valued at $22,794,000 after buying an additional 15,289 shares in the last quarter. Thrivent Financial For Lutherans increased its stake in shares of Amedisys by 3.8% in the first quarter. Thrivent Financial For Lutherans now owns 15,703 shares of the health services provider’s stock valued at $802,000 after buying an additional 570 shares in the last quarter. Russell Investments Group Ltd. bought a new stake in shares of Amedisys during the fourth quarter valued at $870,000. Finally, Great West Life Assurance Co. Can increased its stake in shares of Amedisys by 8.0% in the first quarter. Great West Life Assurance Co. Can now owns 40,062 shares of the health services provider’s stock valued at $2,045,000 after buying an additional 2,960 shares in the last quarter. 99.10% of the stock is currently owned by institutional investors.

About Amedisys

Amedisys, Inc is a healthcare services company. The Company’s segments are Home Health, Hospice, Personal Care and Other. The Company is a provider of home health, hospice and personal care services. As of December 31, 2016, the Company owned and operated 327 Medicare-certified home healthcare centers, 79 Medicare-certified hospice care centers and 14 personal-care care centers in 34 states within the United States and the District of Columbia.

Analyst Recommendations for Amedisys (NASDAQ:AMED)

Receive News & Ratings for Amedisys Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.